n.a. (ZLCS)

5.39
0.00 (0.00)
NASDAQ
Prev Close 5.39
Open 5.60
Day Low/High 5.26 / 5.60
52 Wk Low/High 3.78 / 16.90
Volume 177.07K
Exchange NASDAQ
P/E Ratio 0.34
Div & Yield N.A. (N.A)
22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

Zalicus Reports Financial Results For The First Quarter 2012

Zalicus Reports Financial Results For The First Quarter 2012

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the first quarter ended March 31, 2012.

Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, Into Multiple Phase 2a Clinical Trials For The Treatment Of Pain

Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, Into Multiple Phase 2a Clinical Trials For The Treatment Of Pain

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is advancing Z160, ...

Zalicus Completes Patient Enrollment In Phase 2b Clinical Trial Of Synavive In Rheumatoid Arthritis

Zalicus Completes Patient Enrollment In Phase 2b Clinical Trial Of Synavive In Rheumatoid Arthritis

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed ...

Zalicus Provides Oncology Research Collaboration Update

Zalicus Provides Oncology Research Collaboration Update

Zalicus Inc. (NASDAQ: ZLCS) provided an update today on its research collaboration with Novartis, based on its combination High Throughput Screening (cHTS) platform.

Zalicus Discovers Novel Multi-Target Mechanism For The Treatment Of Multiple Myeloma

Zalicus Discovers Novel Multi-Target Mechanism For The Treatment Of Multiple Myeloma

Zalicus Inc. (NASDAQ: ZLCS) today announced the publication of new preclinical data in Molecular Cancer Therapeutics, a Journal published by the American Association for Cancer Research.

8 Stocks Under $10 Moving Higher

8 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2011

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2011

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the fourth quarter and year ended December 31, 2011.

Zalicus Successfully Completes Phase 1 Clinical Study With Reformulated Z160

Zalicus Successfully Completes Phase 1 Clinical Study With Reformulated Z160

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion ...

Zalicus To Present At Cowen And Company 32nd Annual Health Care Conference

Zalicus To Present At Cowen And Company 32nd Annual Health Care Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus And Hydra Collaborate To Advance Novel Ion Channel Product Candidates For The Treatment Of Pain

Zalicus And Hydra Collaborate To Advance Novel Ion Channel Product Candidates For The Treatment Of Pain

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases and Hydra Biosciences, Inc.

Zalicus To Present At BIO CEO & Investor Conference

Zalicus To Present At BIO CEO & Investor Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At Biotech Showcase 2012 Conference

Zalicus To Present At Biotech Showcase 2012 Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At Oppenheimer 22nd Annual Healthcare Conference

Zalicus To Present At Oppenheimer 22nd Annual Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus Initiates Phase 1 Clinical Trial Of Z160

Zalicus Initiates Phase 1 Clinical Trial Of Z160

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of a Phase 1 ...

Zalicus Reports Financial Results For The Third Quarter 2011

Zalicus Reports Financial Results For The Third Quarter 2011

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the third quarter ended September 30, 2011.

Zalicus To Present At Sixth Annual JMP Securities Healthcare Conference

Zalicus To Present At Sixth Annual JMP Securities Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At UBS Global Life Sciences Conference

Zalicus To Present At UBS Global Life Sciences Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At Rodman & Renshaw Annual Global Investment Conference

Zalicus To Present At Rodman & Renshaw Annual Global Investment Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At Stifel Nicolaus 2011 Healthcare Conference

Zalicus To Present At Stifel Nicolaus 2011 Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present At Wedbush Securities 2011 Life Sciences Management Access Conference

Zalicus To Present At Wedbush Securities 2011 Life Sciences Management Access Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus Stock Gaps Down On Today's Open (ZLCS)

Zalicus Stock Gaps Down On Today's Open (ZLCS)

Shares of Zalicus (Nasdaq:ZLCS) were gapping down Monday morning with an open price 15.5% lower than Friday's closing price. The stock closed at $1.61 yesterday and opened today's trading at $1.36.

Zalicus To Present At Canaccord Genuity Growth Conference

Zalicus To Present At Canaccord Genuity Growth Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus Reports Financial Results For The Second Quarter 2011

Zalicus Reports Financial Results For The Second Quarter 2011

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the second quarter ended June 30, 2011.

Movers Roundup: Peabody Energy, Medtronic

Movers Roundup: Peabody Energy, Medtronic

Movers roundup: Peabody Energy shares rise; Medtronic shares fall

Zalicus Initiates Phase 2b Clinical Trial Of Synavive In Rheumatoid Arthritis

Zalicus Initiates Phase 2b Clinical Trial Of Synavive In Rheumatoid Arthritis

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY...

10 Pharma Stocks Under $3

10 Pharma Stocks Under $3

Expect these to deliver strong returns, building on industry profitability and favorable company fundamentals.

Zalicus To Present At The 10th Annual World Pharma Conference

Zalicus To Present At The 10th Annual World Pharma Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced two presentations at the 10 th ...

Zalicus To Present At Jefferies 2011 Global Healthcare Conference

Zalicus To Present At Jefferies 2011 Global Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus Selected To Join The NASDAQ Biotechnology Index

Zalicus Selected To Join The NASDAQ Biotechnology Index

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that it has been selected to join...